• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cured but breathless: the growing burden of DIILD in cancer survivors.

作者信息

Li Jing-Xing, Cheng Wen-Chien

机构信息

Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

出版信息

Nat Rev Clin Oncol. 2025 Aug 13. doi: 10.1038/s41571-025-01064-4.

DOI:10.1038/s41571-025-01064-4
PMID:40804487
Abstract
摘要

相似文献

1
Cured but breathless: the growing burden of DIILD in cancer survivors.治愈但呼吸急促：癌症幸存者中药物性间质性肺疾病日益加重的负担
Nat Rev Clin Oncol. 2025 Aug 13. doi: 10.1038/s41571-025-01064-4.
2
Severe drug-induced interstitial lung disease after photoimmunotherapy with cetuximab-sarotalocan sodium in a patient with oropharyngeal cancer: A case report.西妥昔单抗-沙罗他卡钠光免疫疗法治疗口咽癌患者后发生严重药物性间质性肺疾病：一例报告
Respir Med Case Rep. 2025 Jul 5;57:102260. doi: 10.1016/j.rmcr.2025.102260. eCollection 2025.
3
Incidence and risk of drug-induced interstitial lung disease associated with anti-neoplastic drugs.抗肿瘤药物相关药物性间质性肺疾病的发病率和风险
Expert Opin Drug Saf. 2025 Aug;24(8):899-907. doi: 10.1080/14740338.2025.2472918. Epub 2025 Mar 3.
4
Mobile Apps and Quality of Life in Patients With Breast Cancer and Survivors: Systematic Literature Review.移动应用程序与乳腺癌患者和幸存者的生活质量：系统文献综述。
J Med Internet Res. 2023 Jul 26;25:e42852. doi: 10.2196/42852.
5
Parents' perceptions and experiences of physical activity in childhood cancer survivors in Singapore: a qualitative study.新加坡儿童癌症幸存者父母对其身体活动的认知与经历：一项定性研究
Singapore Med J. 2025 Jun 1;66(6):314-320. doi: 10.4103/singaporemedj.SMJ-2022-122. Epub 2023 May 30.
6
Direct Economic Burden of Post-Cancer Treatment Pain Among Cancer Survivors in the United States: A Population-Based Retrospective Longitudinal Study.美国癌症幸存者癌症治疗后疼痛的直接经济负担：一项基于人群的回顾性纵向研究。
Int J Health Plann Manage. 2025 Jul;40(4):935-947. doi: 10.1002/hpm.3932. Epub 2025 Apr 5.
7
Accelerometer measurement error in a randomized physical activity intervention trial in breast cancer survivors was nondifferential but attenuated the intervention effect.在一项针对乳腺癌幸存者的随机体育活动干预试验中，加速度计测量误差无差异，但减弱了干预效果。
Int J Behav Nutr Phys Act. 2025 May 26;22(1):59. doi: 10.1186/s12966-025-01760-5.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.儿童癌症幸存者50岁后的健康状况：来自儿童癌症幸存者研究的报告。
J Clin Oncol. 2025 Aug 11:JCO2500385. doi: 10.1200/JCO-25-00385.
10
Diabetes in childhood cancer survivors: emerging concepts in pathophysiology and future directions.儿童癌症幸存者中的糖尿病：病理生理学的新观念与未来方向
Front Med (Lausanne). 2023 Aug 22;10:1206071. doi: 10.3389/fmed.2023.1206071. eCollection 2023.

本文引用的文献

1
F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors.非癌性肺组织对F-FDG-PET/CT的摄取作为免疫检查点抑制剂诱导的间质性肺疾病的预测指标
Acad Radiol. 2025 Feb;32(2):1026-1035. doi: 10.1016/j.acra.2024.08.043. Epub 2024 Sep 2.
2
Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective.曲妥珠单抗-德鲁替康（T-DXd）治疗相关肺毒性的管理：加拿大视角。
Curr Oncol. 2023 Aug 30;30(9):8019-8038. doi: 10.3390/curroncol30090582.
3
Optimizing the safety of antibody-drug conjugates for patients with solid tumours.
优化抗体药物偶联物在实体瘤患者中的安全性。
Nat Rev Clin Oncol. 2023 Aug;20(8):558-576. doi: 10.1038/s41571-023-00783-w. Epub 2023 Jun 9.
4
Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.曲妥珠单抗 deruxtecan 治疗 - 突变型非小细胞肺癌。
N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.
5
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.癌症患者发生免疫相关不良反应后免疫检查点抑制剂的再次挑战
JAMA Oncol. 2020 Jun 1;6(6):865-871. doi: 10.1001/jamaoncol.2020.0726.
6
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
7
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.免疫检查点抑制剂相关性肺炎对 NSCLC 患者接受免疫检查点治疗生存的影响。
J Thorac Oncol. 2019 Mar;14(3):494-502. doi: 10.1016/j.jtho.2018.11.016. Epub 2018 Nov 30.
8
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.免疫检查点抑制剂相关致命性毒性作用：系统评价和荟萃分析。
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.